Taysha Gene Therapies Announces Second Patient Dosed With TSHA-102 In The REVEAL Phase 1/2 Adult Trial For The Treatment Of Rett Syndrome
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies has announced that the second patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial for the treatment of Rett syndrome. The company expects to complete enrollment in the low-dose cohort in Q4 2023 and to dose the first pediatric patient in Q1 2024. The FDA has cleared the Investigational New Drug application for TSHA-102 in pediatric patients, and the company has submitted a Clinical Trial Application to the UK's MHRA.
September 26, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies' progress in the REVEAL Phase 1/2 trial for TSHA-102 could potentially impact the company's stock positively. The company's plans to complete enrollment in Q4 2023 and to dose the first pediatric patient in Q1 2024 could also influence investor sentiment.
The announcement of the second patient being dosed in the REVEAL Phase 1/2 trial indicates progress in Taysha's development of TSHA-102. The company's plans for future milestones, including completing enrollment in the low-dose cohort and dosing the first pediatric patient, could potentially boost investor confidence and positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100